Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 4
2016 7
2017 3
2018 4
2019 1
2020 3
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Potentiating adoptive cell therapy using synthetic IL-9 receptors.
Kalbasi A, Siurala M, Su LL, Tariveranmoshabad M, Picton LK, Ravikumar P, Li P, Lin JX, Escuin-Ordinas H, Da T, Kremer SV, Sun AL, Castelli S, Agarwal S, Scholler J, Song D, Rommel PC, Radaelli E, Young RM, Leonard WJ, Ribas A, June CH, Garcia KC. Kalbasi A, et al. Among authors: siurala m. Nature. 2022 Jul;607(7918):360-365. doi: 10.1038/s41586-022-04801-2. Epub 2022 Jun 8. Nature. 2022. PMID: 35676488 Free PMC article.
Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma.
Watanabe K, Gomez AM, Kuramitsu S, Siurala M, Da T, Agarwal S, Song D, Scholler J, Rotolo A, Posey AD, Rook AH, Haun PL, Ruella M, Young RM, June CH. Watanabe K, et al. Among authors: siurala m. Blood Adv. 2023 Jul 25;7(14):3416-3430. doi: 10.1182/bloodadvances.2022008327. Blood Adv. 2023. PMID: 37058474 Free PMC article.
Publisher Correction: Potentiating adoptive cell therapy using synthetic IL-9 receptors.
Kalbasi A, Siurala M, Su LL, Tariveranmoshabad M, Picton LK, Ravikumar P, Li P, Lin JX, Escuin-Ordinas H, Da T, Kremer SV, Sun AL, Castelli S, Agarwal S, Scholler J, Song D, Rommel PC, Radaelli E, Young RM, Leonard WJ, Ribas A, June CH, Garcia KC. Kalbasi A, et al. Among authors: siurala m. Nature. 2022 Dec;612(7938):E10. doi: 10.1038/s41586-022-05548-6. Nature. 2022. PMID: 36380037 Free PMC article. No abstract available.
GMCSF-armed vaccinia virus induces an antitumor immune response.
Parviainen S, Ahonen M, Diaconu I, Kipar A, Siurala M, Vähä-Koskela M, Kanerva A, Cerullo V, Hemminki A. Parviainen S, et al. Among authors: siurala m. Int J Cancer. 2015 Mar 1;136(5):1065-72. doi: 10.1002/ijc.29068. Epub 2014 Jul 10. Int J Cancer. 2015. PMID: 25042001 Free article.
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.
Havunen R, Santos JM, Sorsa S, Rantapero T, Lumen D, Siurala M, Airaksinen AJ, Cervera-Carrascon V, Tähtinen S, Kanerva A, Hemminki A. Havunen R, et al. Among authors: siurala m. Mol Ther Oncolytics. 2018 Nov 6;11:109-121. doi: 10.1016/j.omto.2018.10.005. eCollection 2018 Dec 21. Mol Ther Oncolytics. 2018. PMID: 30569015 Free PMC article.
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.
Cervera-Carrascon V, Quixabeira DCA, Santos JM, Havunen R, Zafar S, Hemminki O, Heiniö C, Munaro E, Siurala M, Sorsa S, Mirtti T, Järvinen P, Mildh M, Nisen H, Rannikko A, Anttila M, Kanerva A, Hemminki A. Cervera-Carrascon V, et al. Among authors: siurala m. Oncoimmunology. 2020 May 22;9(1):1761229. doi: 10.1080/2162402X.2020.1761229. Oncoimmunology. 2020. PMID: 32923123 Free PMC article.
23 results